Executive Keynote Speakers: Click on Photos to learn more
Drug Hunter, Pharmaceutical Executive, Disruptive Technology Advocate. Senior Lecturer at MIT & Chief Scientific Officer, Relay Therapeutics, Cambridge MA. He is a co-inventor of the HCV protease inhibitor Incivek (telaprevir), Agenerase (amprenavir) and Lexiva (fosamprenavir), Vertex’s two marketed drugs for the treatment of HIV.
David MEEK joined Ipsen as CEO in July 2016. He started his career at Johnson & Johnson and Janssen Pharmaceutica (1989-2004).
Global Head, Johnson & Johnson Innovation. He joined the J&J Family of Companies from the MIT, where he was the founding Executive Director of the Koch Institute for Integrative Cancer Research. His experience includes clinical product development, operations oversight, licensing and acquisitions, capital fund raising, company creation, and building relationships with key thought-leaders.
Expert Panel Speakers:
Dr Shahin Gharakhanian is the Founder of the Boston-Paris Biotechnology Summit. Shahin specializes in Drug & Vaccine Clinical Development Medical Affairs.
CEO of Nanobiotix Corp, Nanobiotix US affiliate. Patrick focused on neuropharmacology research in academia/industry, both in France and US (1986-1990) then Synthélabo Recherche in 1991.
Joseph F. Merola, MD, MMSc, is Assistant Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School.
Mark, PhD, FRAPS, Senior VP, Regulatory Affairs and Quality Assurance at Nightstar Therapeutics. He has over two decades of experience guiding global regulatory strategies for clinical, nonclinical and chemistry, manufacturing and controls (CMC) in multiple therapeutic areas.
Cami Graham, MD, MPH is an Assistant Professor of Medicine at Harvard Medical School. VP of Corporate and Medical Affairs at Trek Therapeutics & Co-Director of the Viral Hepatitis Center at Beth Israel Deaconess Medical Center.
Dr. Jean-Marie Vallet is a French-American Life Sciences Executive with 35 years of professional experience in several capacities within the pharma & biotech industry, moving to the business side after starting as a scientist.
Dr. La Monica joined the J&J Boston Innovation Center in 2013 as Senior Director of ID and Vaccines Scientific Innovation. He has managed research teams involved in anti-HCV research, cancer vaccines or cancer immunotherapy.
CEO Otosense, moved to Boston early 2014. In a few months, Sebastien was featured at TEDx Cambridge and OtoSense first product was awarded best app of the year at Mobile World Congress. Raising money from local, solid angel groups...
Dr Nowak, Managing Partner of Nowak Ventures LLC, is an experienced healthcare and high tech investor in small cap public and venture-backed private companies. He has prior experience with life sciences focused investment funds, family offices and boutique investment banks.
Veleka, Co-Leader, FDA Practice, Partner at McDermott, Will & Emery in Washington, DC, is an experienced lawyer in the life sciences industry, advising pharmaceutical, biotechnology, technology and medical device companies on FDA regulatory and global compliance matters.
Kevin Scanlon is an investment advisor to Sky Ventures in Boston, MA and a Professor of Practice at Northeastern University. He served as the Chairman of Pasadena Angels Investment Group with ~100 investors that funded over 50 companies in two years.
Founder, Chairman and CEO, Moerae Matrix, Inc. Dr. Lander has been a Partner in Nascent Enterprises, LLC, a venture catalyst partnership commercializing medical inventions, with 26 companies created to date.
Dr. Vivaldi, is EVP, Chief global Therapeutic Operations Officer, of Bioverativ, a Sanofi Company focused on hemophilia, cold agglutinin disease and other rare blood disorders.
Mr. Francis Marsland is General Counsel and Head of Business Development for Vicarius Pharma, which commercializes novel specialty orphan/rare and hospital therapies in European markets on behalf of its partners.
Chairs & Moderators:
Kenneth Kaitin is Professor of Medicine at Tufts University School of Medicine and Director of the Tufts Center for the Study of Drug Development.
Dr. Pravin Chaturvedi is the Chairman of the Scientific Advisory Board for Napo Pharmaceuticals and is the CEO for IndUS and Oceanyx Pharmaceuticals.
Julius is a Manager at Bionest Partners in Paris. Prior to joining Bionest in 2016, Julius worked for 6 years in the healthcare sector, both on the consulting and industry side.
Emmanuelle Trombe, Partner at McDermott, Will & Emery, represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnering, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters.